Crossmark

Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR

Crossref DOI link: https://doi.org/10.1136/jitc-2023-006837

Published Online: 2023-09-21

Published Print: 2023-09

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Ploeg, Emily Maria https://orcid.org/0000-0002-0735-2020
Samplonius, Douwe Freerk https://orcid.org/0000-0002-0613-7150
Xiong, Xiao

Ke, Xiurong https://orcid.org/0000-0001-8982-0950
Hendriks, Mark Alexander Johannes Martinus https://orcid.org/0000-0001-7276-4622
Britsch, Isabel https://orcid.org/0000-0003-4772-9889
van Wijngaarden, Anne Paulien https://orcid.org/0000-0002-8221-1180
Zhang, Hao https://orcid.org/0000-0002-2860-5912
Helfrich, Wijnand https://orcid.org/0000-0001-7004-3995
Funding

Funding for this research was provided by:

KWF Kankerbestrijding (11464)

KWF Kankerbestrijding (6986)
License Information

License valid from 2023-09-21